排序方式: 共有33条查询结果,搜索用时 15 毫秒
1.
Rujira Rujiwetpongstorn Mati Chuamanochan Napatra Tovanabutra Romanee Chaiwarith Siri Chiewchanvit 《The Journal of dermatology》2020,47(6):563-568
Reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-γ autoantibody (AOID) are usually associated with concomitant active opportunistic infections. Data focusing on the treatment of these dermatoses with non-immunosuppressive drugs are still lacking. The aim of this study was to assess the efficacy and safety of acitretin treatment of reactive neutrophilic dermatoses in AOID. We conducted a retrospective review of all patients with AOID who had reactive neutrophilic dermatoses and had been treated with acitretin from January 2008 to December 2018. In total, 23 patients had been diagnosed with AOID, with 27 episodes of reactive neutrophilic dermatoses (20 episodes of Sweet syndrome and seven episodes of generalized pustular eruption) and treated with acitretin. The median effective dose of acitretin was 10 mg/day. The mean initial response was 5.6 ± 2.3 days. The rash had almost or completely cleared within 2 weeks in 70.4% of patients. One case had developed a reversible acitretin-induced liver injury with hepatocellular pattern. The median total duration of treatment was 3 months. In conclusion, this study demonstrates the potential role of acitretin as one of the treatments of choice for reactive neutrophilic dermatoses in AOID, attributable to its favorable response and good tolerability. 相似文献
2.
A retrospective cohort study was conducted to determine the relapse rate of penicilliosis marneffei after the discontinuation of itraconazole secondary prophylaxis in 33 HIV-infected patients who received HAART and had CD4 cell counts of 100 cells/mul or greater for at least 6 months. The observed incidence of relapse of penicilliosis marneffei was zero cases per 641 person-months (95% confidence interval 0-0.6 cases per person-month) after a median follow-up of 18 months (range 6-45). 相似文献
3.
4.
5.
Win M Han Awachana Jiamsakul Sasisopin Kiertiburanakul Oon T Ng Benedict LH Sim Ly P Sun Kinh Van Nguyen Jun Y Choi Man P Lee Wing W Wong Adeeba Kamarulzaman Nagalingeswaran Kumarasamy Fujie Zhang Junko Tanuma Cuong D Do Romanee Chaiwarith Tuti P Merati Evy Yunihastuti Sanjay Pujari Rossana Ditangco Suwimon Khusuwan Jeremy Ross Anchalee Avihingsanon 《Journal of the International AIDS Society》2019,22(1)
6.
7.
Salin Kiratikanon Phichayut Phinyo Rujira Rujiwetpongstorn Jayanton Patumanond Veeraphol Tungphaisal Pongsak Mahanupab Romanee Chaiwarith Napatra Tovanabutra Siri Chiewchanvit Mati Chuamanochan 《The Journal of dermatology》2022,49(1):133-141
Sweet syndrome (SS) has been increasingly reported in patients with adult-onset immunodeficiency (AOID) due to anti-interferon-γ autoantibody who also have concomitant opportunistic infections, especially disseminated non-tuberculous mycobacterial infection (dNTMI). A retrospective study retrieving data from 2011 through 2020 was conducted. We compared clinical characteristics of SS with and without AOID and generated the prediction model and examined the interaction between AOID and dNTMI in the occurrence of SS. Lymphadenopathy, pustular lesions, and leukocytosis are the significant predictors for AOID-associated SS. Adjusted risk differences were 0.58 (95% confidence interval [CI], 0.33–0.83), 0.21 (95% CI, 0.02–0.39), and 0.24 (95% CI, 0.01–0.47), respectively. Based on the analysis of aggregated cross-sectional data, both the overall and the direct effect of AOID increased the prevalence of SS. The indirect effect of AOID on the occurrence of SS might also be mediated through dNTMI or other common opportunistic infections. In addition, there was a trend of positive additive interaction between AOID and dNTMI. Although the test of additive interaction did not reveal statistically significant results, a deviation from additivity of isolated effects might suggest potential causal interaction between AOID and dNTMI. The distinctive clinical syndrome comprising lymphadenopathy, pustular lesions, and leukocytosis in patients with SS should raise the awareness of clinicians to the potential of underlying AOID. 相似文献
8.
Kajohnsak Noppakun Tichanun Narongchai Romanee Chaiwarith Uraiwan Wongsawad Surachet Vongsanim Chidchanok Ruengorn Surapon Nochaiwong 《Annals of medicine》2021,53(1):365
BackgroundTo the best of our knowledge, the effectiveness and safety of lactulose in comparison to sennosides, for the prevention of peritoneal dialysis (PD)-related peritonitis, has never been tested in a randomized study.MethodsWe conducted an open-label, randomized, active-controlled trial in a PD-center in Northern Thailand. Adult patients on PD were enrolled and randomly assigned in a 1:1 ratio into two groups; one group received lactulose 15 mL once daily (n = 50) and the other group received sennosides two tablets daily (n = 50). The primary outcome was time-to-first bacterial peritonitis. The secondary outcomes included a composite of bacterial peritonitis and all-cause mortality. Cox proportional hazards regression was calculated and presented as hazard ratios (HRs) with 95% confidence intervals (CIs).ResultsOne hundred PD patients were recruited (50.0% men; mean age 55.5 ± 13.0 years) in this study. The baseline characteristics of the study participants were similar in both groups. No significant trend towards a higher risk of PD-related peritonitis was observed in the lactulose group (HR, 2.32 [95% CI, 0.92–5.83]; p = .051) compared to the sennosides group. Nevertheless, the secondary outcome was significantly higher in the lactulose group (HR, 2.77 [95% CI, 1.20–6.41]; p = .010). The incidence of adverse events was not substantially different between the two groups; however, diarrhoea was more frequent in the lactulose group (38.0% vs. 18.0%; p = .030) than in the sennosides group.ConclusionsTreatment with lactulose is not more effective than sennosides and cannot be routinely recommended for the prevention of peritonitis among the PD population.
TRIAL REGISTRATION
- Thai Clinical Trial Registry (clinicaltrials.in.th); ID: TCTR20171012001
KEY MESSAGE
- To the best of our knowledge, no randomized controlled trial that compares the efficacy and safety profiles of lactulose versus sennosides for the prevention of PD-related peritonitis among the PD population has been conducted.
- In this open-label, randomized, active-controlled trial, treatment with lactulose is not more effective than sennosides in the prevention of PD-related peritonitis, and it could increase the risk of bacterial PD-related peritonitis.
- Further studies with a larger sample size by incorporated real-world evidence are needed to confirm our findings and to explore strategies to prevent peritonitis among PD patients.
9.